Hejing Biotech announced that the SGT003 injection independently developed by the holding subsidiary Shunjing Pharmaceutical is undergoing phase I/IIa clinical study, and recently completed the enrollment and administration of the first test subjects.

Zhitongcaijing · 3d ago
Hejing Biotech announced that the SGT003 injection independently developed by the holding subsidiary Shunjing Pharmaceutical is undergoing phase I/IIa clinical study, and recently completed the enrollment and administration of the first test subjects.